Real Transformation
For Patients & Stakeholders

Biopharmaceutical Treatments for
Neglected and rare diseases

KaloBios is advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. We will lead by example in our industry with creative and concrete operational change, such as our Responsible Pricing Model.

Achieving real transformation for patients and all our stakeholders will require us to work transparently and collaboratively to drive a reasonable return and impact across society.


A commitment to define and develop transparent, responsible pricing 

KaloBios’ Responsible Pricing Model:

  • Responsible Pricing = affordable for patients and payers, transparent for stakeholders and delivers a reasonable return for the company taking the risk of bringing products to patients.
  • We plan to price our products at overall cost, plus a reasonable and transparent profit margin, if and when we commercialize them.
  • In the case of benznidazole, for instance, the price will be cost plus a modest profit margin.We are not conducting original research on benznidazole and therefore do not plan to incorporate an “R&D premium” into the price.
  • We will publicly share the key elements that make up the pricing of our products.
  • We will seek input from key stakeholders on what would constitute a reasonable return.
  • We will not take arbitrary price increases on our products and will limit any increase to no more than the rate of inflation or Consumer Price Index and to no more than once a year, if at all.
  • We will not engage in aggressive or predatory pricing policies or “price-gouging.”
  • We plan to ensure patients, irrespective of their ability to pay, will have access to benznidazole, if and when KaloBios commercializes the product for Chagas disease in the United States.
  • In developing countries, we plan to make benznidazole available at, or near cost and plan to work with partners on creating access programs to ensure patients in need receive the medication.



Cameron Durrant, MD, MBA

Chairman and CEO

  • Senior pharmaceutical and biotech exec, turnaround specialist
  • Senior exec roles at Pharmacia/Pfizer, J+J in US, Merck, GSK in Europe; experience as Exec Chairman, CEO and CFO; CEO roles at three specialty pharma groups
  • Expertise in anti-infectives, pediatrics, oncology

Morgan Lam

Chief Scientific Officer

  • Extensive industry experience in clinical research
  • Head of Clinical Operations and Development KaloBios
  • Executive Director, Medical Affairs, Geron

Dave Tousley, MBA, CPA

Interim Chief Financial Officer

  • More than 35 years experience in biotech, spec pharma, big pharma
  • Senior exec roles, President, COO, CFO
  • Pasteur, Merieux, Connaught, AVAX, airPharma, PediaMed, DARA Biosciences

Tariq Arshad, MD, MBA

Consultant focused on medical affairs

  • Extensive industry experience in clinical development
  • Experienced in orphan, pediatrics, oncology, pediatric oncology, immunology
  • Pharmacia/Pfizer, Genentech, Xoma

Niv Caviar, MBA

Consultant focused on corporate/business development

  • Senior functional roles in marketing, business development, strategic planning
  • Senior exec roles, CEO, EVP-CBO, CFO, VP Bus Dev
  • La Jolla Pharma, Allergan, Suneva, SpineOvations, Affymetrix, Accenture

Christopher Bowe

Consultant focused on corporate affairs

  • Deep experience advising CEOs on articulating, executing strategy through corporate affairs
  • Former Strategic Affairs advisor at Schering-Plough
    Industry thought leader, prior award-winning writer Financial Times

Steve Pal, MBA

Consultant focused on commercial

  • Global pharma and consumer healthcare product commercialisation
  • Former Corporate VP Global Strategic Marketing, Health Outcomes, Strategy and Research, Global Medical Affairs, Allergan


Cameron Durrant MD, MBA

Dr. Cameron Durrant is the Chairman and Chief Executive Officer of KaloBios, since March 1, 2016. He was elevated to that position after serving on the board of directors starting January 7, 2016.

Dr. Durrant’s expertise and business career has revolved around transformations, whether for brands, business units, or small companies. He has particular therapeutic experience in infectious diseases, pediatrics and oncology – coupled with experience as a practicing physician.

He has served as board chairman, lead independent director and as CEO for several specialty pharma or biotech companies in both the private and public sector. He has been involved in several exits and has raised significant funding from a variety of sources.

He is currently a founding director of a private nanotech oncology company, Bexion Pharmaceuticals, a board member of Immune Pharmaceuticals, a publicly traded immune-oncology biotech, and on the board of two private medical device companies. Dr. Durrant is also founder of the start-up Taran Pharma Limited, a private, semi-virtual specialty pharma company developing and registering treatments in Europe for orphan conditions

Previously, Dr. Durrant was president and CEO of ECR Pharmaceuticals and a corporate officer of Hi-Tech Pharmacal; and the founder, Chairman, CEO and CFO of PediatRx, Inc., which marketed therapies for pediatric care, orphan conditions and oncology supportive care.

His career has been built on extensive experience – including commercial, P&L, US and global responsibilities – as an operating executive at blue-chip pharmaceutical companies. Dr. Durrant has been President and CEO of PediaMed Pharmaceuticals, a company focused on bring important medicines to children in the US; and held senior executive positions at Johnson & Johnson and Pharmacia. He also had earlier roles at GlaxoSmithKline and Merck.

He is a prior regional winner of the Ernst and Young ‘Entrepreneur of the Year’ award.

Dr. Durrant earned his MD from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, and his MRCGP from the Royal College of General Practitioners, London, UK. He practiced medicine for eight years in the UK and Australia. He also earned his MBA from Henley Management College, Oxford, UK.

Ronald Barliant

Ronald Barliant was appointed to the KaloBios board on January 7, 2016.

Mr. Barliant is of counsel with the Chicago law firm Goldberg Kohn, where he had been a principal in the Bankruptcy & Creditors’ Rights Group after joining in September 2002. He has represented debtors and creditors in complex bankruptcy cases, and counseled major financial institutions, business firms and boards of directors in connection with workouts.

He served as a United States bankruptcy judge for the Northern District of Illinois from 1988 to 2002, and as a visiting judge in the District of Delaware in 2002.

He is a member of the board of directors of a closely held information technology company and the board of the estate representative supervising the liquidation of assets in the Global Crossing case. And he was previously a director of a Delaware debtor in the automotive industry. He has also counseled boards of directors and individual directors in connection with their fiduciary duties in distressed situations.

Mr. Barliant has taught debtor-creditor relations at John Marshall Law School and has frequently lectured and participated in panel discussions on bankruptcy-related topics at the invitation of many organizations, including the Federal Judicial Center, the National Conference of Bankruptcy Judges (NCBJ), the American Bankruptcy Institute, the American Bar Association, the American College of Bankruptcy, the Commercial Finance Association, the Turnaround Management Association, the Chicago Bar Association and LexisNexis Mealey’s.

His published writings include articles on Chapter 11 plans, executory contracts, preferences, the anti-trust litigation in the United Airlines case (in which he represented an indenture trustee/defendant), and asbestos bankruptcies. He was a member of the board of governors of the NCBJ from 1998 to 2000 and of the NCBJ’s Endowment for Education from 1997 to 1998. In addition, he served on national judicial committees and on working groups considering technology issues and the treatment of mass torts in bankruptcy cases.

Mr. Barliant has been recognized annually by the Leading Lawyers Network, Super Lawyers, and Best Lawyers. He was named by Chambers USA 2014 as a leading lawyer in the United States in Bankruptcy/Restructuring. He is currently a member of the ABI (Business Reorganization Committee), ABA (Business Law Section), and NCBJ (Former Judges Section) and is a former Chair of the Bankruptcy and Reorganizations Committee of the CBA. He is a Fellow in the American College of Bankruptcy and served as the College’s Regent for the Seventh Circuit.

Timothy Morris

Timothy Morris has over 30 years of professional finance and accounting experience, of which 19 have been as a Chief Financial Officer. He has raised over $980MM in equity and convertible securities for six companies. He has extensive deal experience with over 65 transactions with a combined value in excess of $2Bn. Mr. Morris currently serves as the CFO of AcelRx Pharmaceuticals, a publically traded specialty pharmaceutical company with two late-stage products for acute pain, starting in 2014. He added the responsibilities of Head of Business Development in 2015.

Previously, Mr. Morris served as a CFO, SVP Finance and Global Corporate Development of VIVUS, Inc. from November 2004 to December 2013. At VIVUS Mr. Morris oversaw finance, corporate development, IT, human resources, legal, and investor relations functions.

From September 2001 to November 2004, Mr. Morris was CFO, SVP Finance, Manufacturing and Administration for Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company. He was a member of the Office of the President from August 2004 to November 2004.

Mr. Morris serves as a non-executive director of PAION Inc., the US subsidiary of PAION AG, a publically traded company based in Germany. He graduated cum laude with a BS in Business with emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant.

Dale Chappell, M.D., M.B.A.

Dale Chappell is the managing member of Black Horse Capital Management LLC, a private investment manager that specializes in biopharmaceuticals with a particular focus on distressed and turn around situations.

Dr. Chappell was previously an associate with Chilton Investment Company covering healthcare. Dr. Chappell was also as an analyst at W.P. Carey & Company. Before moving into the business sector, Dr. Chappell was a Howard Hughes Medical Institute fellow at the National Cancer Institute where he studied tumor immunology.

Dr. Chappell received his medical doctorate from Dartmouth Medical School and his masters of business administration from Harvard Business School.

Ezra M. Friedberg

Ezra is a seasoned investor with over twenty years of investing experience across public and private companies. His investments include classic private equity, venture capital, distressed opportunities/assets and property throughout the United States, Canada, and overseas.

Ezra serves as founder and general partner of Multiplier Capital, a fund focused on lending opportunities to sponsor-backed growth companies, and is a member of the fund’s credit committee. Separately, Ezra owns and operates other financial services businesses.

Ezra is a graduate of Johns Hopkins University. He has founded and is an active member of several community and civic organizations, including a nonprofit employment agency. Ezra also serves as an advisor to his family’s global charitable foundations.